Stock Track | NovoCure Soars 26.67% in Pre-market on FDA Approval for Pancreatic Cancer Treatment

Stock Track

02/12

NovoCure's stock surged 26.67% in pre-market trading following the U.S. Food and Drug Administration's approval of its Optune Pax® device for the treatment of locally advanced pancreatic cancer.

The FDA approval, announced by the company, marks the first new treatment for this condition in nearly 30 years. Optune Pax is a wearable device that delivers Tumor Treating Fields (TTFields) noninvasively and is approved for use in combination with gemcitabine and nab-paclitaxel chemotherapy.

The regulatory decision is based on positive results from the Phase 3 PANOVA-3 clinical trial, which demonstrated a statistically significant improvement in median overall survival for patients treated with Optune Pax and chemotherapy compared to chemotherapy alone. The trial met its primary endpoint, showing a median overall survival of 16.2 months versus 14.2 months for the control group.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/1158168445"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1158168445\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1158168445?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-12 17:46","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1158168445","market":"hk","top_or_hot":-1,"title":"Stock Track | NovoCure Soars 26.67% in Pre-market on FDA Approval for Pancreatic Cancer Treatment","media":"Stock Track","content":"<p>NovoCure's stock surged 26.67% in pre-market trading following the U.S. Food and Drug Administration's approval of its Optune Pax® device for the treatment of locally advanced pancreatic cancer.</p><p>The FDA approval, announced by the company, marks the first new treatment for this condition in nearly 30 years. Optune Pax is a wearable device that delivers Tumor Treating Fields (TTFields) noninvasively and is approved for use in combination with gemcitabine and nab-paclitaxel chemotherapy.</p><p>The regulatory decision is based on positive results from the Phase 3 PANOVA-3 clinical trial, which demonstrated a statistically significant improvement in median overall survival for patients treated with Optune Pax and chemotherapy compared to chemotherapy alone. The trial met its primary endpoint, showing a median overall survival of 16.2 months versus 14.2 months for the control group.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | NovoCure Soars 26.67% in Pre-market on FDA Approval for Pancreatic Cancer Treatment</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | NovoCure Soars 26.67% in Pre-market on FDA Approval for Pancreatic Cancer Treatment\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time smaller\">2026-02-12 17:46</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>NovoCure's stock surged 26.67% in pre-market trading following the U.S. Food and Drug Administration's approval of its Optune Pax® device for the treatment of locally advanced pancreatic cancer.</p><p>The FDA approval, announced by the company, marks the first new treatment for this condition in nearly 30 years. Optune Pax is a wearable device that delivers Tumor Treating Fields (TTFields) noninvasively and is approved for use in combination with gemcitabine and nab-paclitaxel chemotherapy.</p><p>The regulatory decision is based on positive results from the Phase 3 PANOVA-3 clinical trial, which demonstrated a statistically significant improvement in median overall survival for patients treated with Optune Pax and chemotherapy compared to chemotherapy alone. The trial met its primary endpoint, showing a median overall survival of 16.2 months versus 14.2 months for the control group.</p>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"NVCR","symbol_name":"NovoCure Limited","start_time":0,"source_url":"","article_id":"1158168445","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1158168445","pubTimestamp":1770889594,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"NovoCure's stock surged 26.67% in pre-market trading following the U.S. Food and Drug Administration's approval of its Optune Pax® device for the treatment of locally advanced pancreatic cancer.The...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"NVCR":"NovoCure Limited"},"translate_title":"个股追踪|NovoCure上市前暴涨26.67%获FDA批准治疗胰腺癌","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NVCR":1},"content_text":"NovoCure's stock surged 26.67% in pre-market trading following the U.S. Food and Drug Administration's approval of its Optune Pax® device for the treatment of locally advanced pancreatic cancer.The FDA approval, announced by the company, marks the first new treatment for this condition in nearly 30 years. Optune Pax is a wearable device that delivers Tumor Treating Fields (TTFields) noninvasively and is approved for use in combination with gemcitabine and nab-paclitaxel chemotherapy.The regulatory decision is based on positive results from the Phase 3 PANOVA-3 clinical trial, which demonstrated a statistically significant improvement in median overall survival for patients treated with Optune Pax and chemotherapy compared to chemotherapy alone. The trial met its primary endpoint, showing a median overall survival of 16.2 months versus 14.2 months for the control group.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}